title: Lentivirus-Mediated Knockdown of Myosin VI Inhibits Cell Proliferation of Breast Cancer Cell.
abstract: Myosin VI (MYO6) is a unique member of the myosin superfamily, and almost no experimental studies link MYO6 to tumorigenesis of breast cancer. However, previous microarray data demonstrated that MYO6 was frequently overexpressed in breast cancer tissues. In this study, to further develop its role in breast cancer, endogenous expression of MYO6 was significantly inhibited in breast cancer ZR-75-30 and MDA-MB-231 cells using lentivirus-mediated RNA interference. Quantitative polymerase chain reaction and western blot were applied to detect the expression level of MYO6. Cell viability of both cell lines was measured by methylthiazol tetrazolium and colony formation assays. Besides, cell cycle assay was utilized to acquire the distribution information of cell phase. The results demonstrated that knockdown of MYO6 markedly reduced cell viability and colony formation, as well as suppressed cell cycle progression in breast cancer cells. The results suggested that MYO6 played a vital role in breast cancer cells and might provide useful information for diagnosis and therapy of human breast cancer in future.
authors.affiliation: 1 Department of General Surgery, Zhongshan Hospital, Fudan University , Shanghai, China .
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
authors.affiliation: 2 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China .
authors.forename: Biyun
authors.initials: B
authors.lastname: Wang
authors.affiliation: 1 Department of General Surgery, Zhongshan Hospital, Fudan University , Shanghai, China .
authors.forename: Wei
authors.initials: W
authors.lastname: Zhu
authors.affiliation: 1 Department of General Surgery, Zhongshan Hospital, Fudan University , Shanghai, China .
authors.forename: Ziang
authors.initials: Z
authors.lastname: Yang
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000473:pathology*; D053148:Caspase 3 / Q000096:biosynthesis / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D055785:Gene Knockdown Techniques; D017930:Genes, Reporter; D005822:Genetic Vectors / Q000235:genetics*; D057809:HEK293 Cells; D006801:Humans; D016086:Lentivirus / Q000235:genetics*; D008969:Molecular Sequence Data; D018995:Myosin Heavy Chains / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D011065:Poly(ADP-ribose) Polymerases / Q000096:biosynthesis / Q000235:genetics; D034622:RNA Interference; D060888:Real-Time Polymerase Chain Reaction; D014161:Transduction, Genetic; D014410:Tumor Stem Cell Assay
chemical_list: D009363:Neoplasm Proteins; C089785:myosin VI; D011065:Poly(ADP-ribose) Polymerases; C505407:CASP3 protein, human; D053148:Caspase 3; D018995:Myosin Heavy Chains
keywords: RNA interference; breast cancer; cell proliferation; myosin VI